BOLERO-3: Everolimus tweaks trastuzumab-resistant metastatic breast cancer Ob.Gyn. News Digital Network CHICAGO – Adding the mTOR inhibitor everolimus to trastuzumab and vinorelbine reduced the risk of progression by 22% in women with trastuzumab-resistant, HER2-positive breast cancer that progressed after taxane therapy. This translated into a gain of ... |
